Trial reportCancer discovery2018
Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial.
Open access · bronzeAbstract readClinical Trial, Phase II
In one paragraph
Trial report in Cancer discovery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 143 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
143citing papers in PubMed, 1 pooled it
12.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
143 citing papers in PubMed, 1 synthesis or guideline pooled it, 234 citations in OpenAlex.
- Circulating tumour DNA and its clinical utility in predicting treatment response or survival in patients with metastatic colorectal cancer: a systematic review and meta-analysis.British journal of cancer · 2022Pooled it
- Circulating tumour DNA to guide rechallenge with cetuximab plus irinotecan in RAS/BRAF wild-type metastatic colorectal cancer: A nonrandomised clinical trial.Clinical and translational medicine · 2026Trial
- Mechanistic Learning for Predicting Survival Outcomes in Head and Neck Squamous Cell Carcinoma.CPT: pharmacometrics & systems pharmacology · 2025Trial
- Evaluation of circulating tumor DNA as a prognostic and predictive biomarker in BRAF V600E mutated colorectal cancer-results from the FIRE-4.5 study.Molecular oncology · 2025Trial
- A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE.Nature communications · 2024Trial
- Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Trial
- Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial.Nature medicine · 2022Trial
- Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, OJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Trial
- Trial
- A guide to understanding tumour evolution through the lens of population genetics.Nature reviews. Cancer · 2026Review
- Tumor evolution: signaling pathways, molecular mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- Review
- Molecular profiling-directed individualized adjuvant therapy in colorectal cancer: Bridging consensus guidelines to clinical disparities.World journal of gastroenterology · 2026Review
- BCL-xL as a therapeutic target in cetuximab-refractory colorectal cancer.Cell death & disease · 2026Article
- Longitudinal omics data analysis: approaches and applications.Computational and structural biotechnology journal · 2026Review
- Article
- How quantum computing can enhance biomarker discovery.Patterns (New York, N.Y.) · 2025Review
- Plasma cfDNA multi-omic biomarkers profiling for detection and stratification of gastric carcinoma.BMC cancer · 2025Article
- miR-196b strictly regulates and reliably predicts the response to cetuximab in colorectal cancer.Cellular & molecular biology letters · 2025Article
- Genomic and Biomarker Innovations in Predicting Kidney Transplant Rejection.Journal of clinical medicine · 2025Review
83 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
36 authors at 3 institutions in 2 countries.
Khurum H KhanDepartment of Medicine, The Royal Marsden NHS Trust, London and Sutton, United Kingdom.
David CunninghamDepartment of Medicine, The Royal Marsden NHS Trust, London and Sutton, United Kingdom.
Benjamin WernerCentre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom.
Georgios VlachogiannisDivision of Molecular Pathology, The Institute of Cancer Research, London and Sutton, United Kingdom.ORCID 0000-0003-3114-8772
Inmaculada SpiteriCentre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom.ORCID 0000-0002-1097-8972
Timon HeideCentre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom.ORCID 0000-0002-1386-7469
Javier Fernandez MateosDivision of Molecular Pathology, The Institute of Cancer Research, London and Sutton, United Kingdom.
Alexandra VatsiouCentre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom.
Andrea LampisDivision of Molecular Pathology, The Institute of Cancer Research, London and Sutton, United Kingdom.
Mahnaz Darvish DamavandiDivision of Molecular Pathology, The Institute of Cancer Research, London and Sutton, United Kingdom.ORCID 0000-0003-0226-2621
Hazel LoteDivision of Molecular Pathology, The Institute of Cancer Research, London and Sutton, United Kingdom.
Ian Said HuntingfordDivision of Molecular Pathology, The Institute of Cancer Research, London and Sutton, United Kingdom.
Somaieh HedayatDivision of Molecular Pathology, The Institute of Cancer Research, London and Sutton, United Kingdom.
Ian ChauDepartment of Medicine, The Royal Marsden NHS Trust, London and Sutton, United Kingdom.
Nina TunariuDepartment of Radiology, The Royal Marsden NHS Trust, Londonand Sutton, United Kingdom.
Giulia MentrastiDivision of Molecular Pathology, The Institute of Cancer Research, London and Sutton, United Kingdom.
Francesco TrevisaniDivision of Molecular Pathology, The Institute of Cancer Research, London and Sutton, United Kingdom.
Sheela RaoDepartment of Medicine, The Royal Marsden NHS Trust, London and Sutton, United Kingdom.
Gayathri AnandappaDepartment of Medicine, The Royal Marsden NHS Trust, London and Sutton, United Kingdom.ORCID 0000-0003-1616-0335
David WatkinsDepartment of Medicine, The Royal Marsden NHS Trust, London and Sutton, United Kingdom.
Naureen StarlingDepartment of Medicine, The Royal Marsden NHS Trust, London and Sutton, United Kingdom.
Janet ThomasDepartment of Medicine, The Royal Marsden NHS Trust, London and Sutton, United Kingdom.
Clare PeckittDepartment of Medicine, The Royal Marsden NHS Trust, London and Sutton, United Kingdom.
Nasir KhanDepartment of Radiology, The Royal Marsden NHS Trust, Londonand Sutton, United Kingdom.
Massimo RuggeDepartment of Medicine and Surgical Pathology, University of Padua, Padua, Italy.
Ruwaida BegumDepartment of Medicine, The Royal Marsden NHS Trust, London and Sutton, United Kingdom.
Blanka HezelovaDepartment of Medicine, The Royal Marsden NHS Trust, London and Sutton, United Kingdom.
Annette BryantDepartment of Medicine, The Royal Marsden NHS Trust, London and Sutton, United Kingdom.
Thomas JonesClinical Genomics, The Centre for Molecular Pathology, The Royal Marsden NHS Trust, London and Sutton, United Kingdom.
Paula ProszekClinical Genomics, The Centre for Molecular Pathology, The Royal Marsden NHS Trust, London and Sutton, United Kingdom.
Matteo FassanDepartment of Medicine and Surgical Pathology, University of Padua, Padua, Italy.ORCID 0000-0001-6515-5482
Jens C HahneDivision of Molecular Pathology, The Institute of Cancer Research, London and Sutton, United Kingdom.
Michael HubankClinical Genomics, The Centre for Molecular Pathology, The Royal Marsden NHS Trust, London and Sutton, United Kingdom.ORCID 0000-0002-2901-0742
Chiara BraconiDepartment of Medicine, The Royal Marsden NHS Trust, London and Sutton, United Kingdom.
Andrea SottorivaCentre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom. nicola.valeri@icr.ac.uk andrea.sottoriva@icr.ac.uk.
Nicola ValeriDepartment of Medicine, The Royal Marsden NHS Trust, London and Sutton, United Kingdom. nicola.valeri@icr.ac.uk andrea.sottoriva@icr.ac.uk.
Royal Marsden NHS Foundation Trust · GBInstitute of Cancer Research · GBUniversity of Padua · IT
Funding
Cancer Research UK 18052Cancer Research UK 22909Cancer Research UK A18052Cancer Research UK A22909Department of HealthWellcome TrustWellcome Trust 105104/Z/14/ZWellcome Trust 202778/B/16/Z
Abstract
Sequential profiling of plasma cell-free DNA (cfDNA) holds immense promise for early detection of patient progression. However, how to exploit the predictive power of cfDNA as a liquid biopsy in the clinic remains unclear. RAS pathway aberrations can be tracked in cfDNA to monitor resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer. In this prospective phase II clinical trial of single-agent cetuximab in
Indexed as
AdultAgedAged, 80 and overClinical Trials as TopicClonal EvolutionColorectal NeoplasmsFemaleHumansLiquid BiopsyMaleMiddle AgedModels, TheoreticalTime-to-TreatmentTreatment Failure
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.